Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

May 26, 2020

Study Completion Date

December 3, 2021

Conditions
Metastatic Triple Negative Breast CancerMetastatic Colorectal Cancer
Interventions
BIOLOGICAL

Talimogene Laherparepvec

Virally based anti-cancer immunotherapy given by direct injection into tumors.

BIOLOGICAL

Atezolizumab

A monoclonal antibody given by intravenous injection.

Trial Locations (17)

1200

Universite Catholique de Louvain Cliniques Universitaires Saint Luc, Brussels

1211

Hopitaux Universitaires de Geneve, Geneva

2170

Liverpool Hospital, Liverpool

3010

Inselspital Bern, Bern

3168

Monash Medical Centre, Clayton

6009

Breast Cancer Research Centre - WA, Nedlands

6150

Fiona Stanley Hospital, Murdoch

9000

Universitair Ziekenhuis Gent, Ghent

10032

Columbia University Medical Center, New York

13353

Charite Universitätsmedizin Berlin, Charité Campus Virchow-Klinikum, Berlin

28007

Hospital General Universitario Gregorio Marañon, Madrid

28034

Hospital Universitario Ramon y Cajal, Madrid

53105

Universitätsklinikum Bonn, Bonn

72076

Universitätsklinik Tübingen, Tübingen

90095

University of California Los Angeles, Los Angeles

11794-9446

Stony Brook University, Stony Brook

08003

Hospital del Mar, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Roche-Genentech

INDUSTRY

lead

Amgen

INDUSTRY

NCT03256344 - Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | Biotech Hunter | Biotech Hunter